Publications
Publications
Show Results For
- All HBS Web
(1,287)
- Faculty Publications (518)
- 2001
- Other Unpublished Work
Clusters of Innovation Initiative: San Diego
The study contains a conceptual framework for assessing the competitiveness of regional economies, an analysis of the San Diego region overall, as well as detailed assessments of two representative clusters—biotechnology/pharmaceuticals and communications. The report... View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (A)
By: Michael Beer and James Weber
Introduces Grey Warner, the vice president of Merck's Latin America region, and his efforts to improve the organizational effectiveness of the region and to introduce a more global business culture and values. Discusses Merck's ethics and values, its Latin American... View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (C): Brazil
By: Michael Beer and James Weber
Examines Merck's change effort in Brazil from the perspective of the local employees. View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (D): Mexico
By: Michael Beer and James Weber
Examines Merck's change effort in Mexico from the perspective of the local employees. View Details
- March 2001 (Revised June 2017)
- Teaching Note
Vyaderm Pharmaceuticals: The EVA Decision
By: Robert Simons and Indra A. Reinbergs
Teaching Note for (9-101-019). View Details
- February 2001 (Revised July 2006)
- Case
Discovering the Future: R&D Strategy at Merck
By: Gary P. Pisano
Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate? View Details
- February 2001
- Teaching Note
CVS: The Web Strategy TN
By: John A. Deighton
Teaching Note for (9-500-008). View Details
- January 2001
- Case
Merck Global Health Initiatives (A)
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details
- January 2001
- Case
Merck Global Health Initiatives (B): Botswana
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details
- January 2001 (Revised May 2003)
- Case
Novartis Pharma: The Business Unit Model
By: Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis
In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing).... View Details
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
- 2001
- Chapter
Publicly Funded Science and the Productivity of the Pharmaceutical Industry
By: Rebecca Henderson and Ian Cockburn
U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While... View Details
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca Henderson and Iain Cockburn
- December 2000 (Revised January 2001)
- Background Note
Promise of Functional Foods, The
By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock
This case presents a definition of functional foods or nutraceuticals (food or food ingredients that could provide a health benefit beyond the traditional nutrients they contain), a description of some of the major obstacles to their commercialization and... View Details
- October 2000 (Revised March 2003)
- Case
Merck & Company: Evaluating a Drug Licensing Opportunity
By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details
- 2000
- Chapter
Millennium Pharmaceuticals, Inc.
By: S. Thomke and A. Nimgade
Keywords: Pharmaceutical Industry
- October 2000
- Case
Procter & Gamble Italy: The Pringles Launch (A)
By: Roy D. Shapiro
Procter & Gamble's (P&G) Pringles potato chips have been a very successful brand. This case reviews the development and first launch in the United States, then in markets around the world. Italy is one of the last countries where Pringles will be launched. Should P&G... View Details
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
- October 2000
- Supplement
Hans Fritz at Novartis Thailand (C)
By: Carin-Isabel Knoop and Michael Y. Yoshino
Supplements the (A) case. View Details